NuCana PLC
NCNA0.046USD
+0.007+17.90%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
280.15KCap. mercado
PérdidaP/E TTM
Más Datos de NuCana PLC Compañía
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3’-deoxyadenosine (3’-Da). The Company is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. Its pipeline also includes Acelari, which is a ProTide transformation of the nucleoside analog gemcitabine. The Company’s subsidiaries include NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited.
Información de la empresa
Símbolo de cotizaciónNCNA
Nombre de la empresaNuCana PLC
Fecha de salida a bolsaSep 28, 2017
Director ejecutivo- -
Número de empleados20
Tipo de seguridadDepository Receipt
Fin del año fiscalSep 28
DirecciónLochside House
CiudadEDINBURGH
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited Kingdom
Código postalEH12 9DT
Teléfono4401313571111
Sitio Webhttps://www.nucana.com/
Símbolo de cotizaciónNCNA
Fecha de salida a bolsaSep 28, 2017
Director ejecutivo- -
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Martin Mellish
Mr. Martin Mellish
Non-Executive Independent Director
Non-Executive Independent Director
1.33K
+18.87%
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
749.00
+298.40%
Dr. Bali Muralidhar, M.D., Ph.D
Dr. Bali Muralidhar, M.D., Ph.D
Non-Executive Independent Director
Non-Executive Independent Director
22.00
--
Dr. Jeffrey D. Bloss, M.D.
Dr. Jeffrey D. Bloss, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andrew Kay
Mr. Andrew Kay
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Cyrille Leperlier, M.D.
Dr. Cyrille Leperlier, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Christopher F. Brinzey
Mr. Christopher F. Brinzey
Investor Relations
Investor Relations
--
--
Dr. David Harrison, M.D.
Dr. David Harrison, M.D.
Head - Translational Studies
Head - Translational Studies
--
--
Mr. Adam George
Mr. Adam George
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ian Webster
Mr. Ian Webster
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Martin Mellish
Mr. Martin Mellish
Non-Executive Independent Director
Non-Executive Independent Director
1.33K
+18.87%
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
749.00
+298.40%
Dr. Bali Muralidhar, M.D., Ph.D
Dr. Bali Muralidhar, M.D., Ph.D
Non-Executive Independent Director
Non-Executive Independent Director
22.00
--
Dr. Jeffrey D. Bloss, M.D.
Dr. Jeffrey D. Bloss, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andrew Kay
Mr. Andrew Kay
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Cyrille Leperlier, M.D.
Dr. Cyrille Leperlier, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Sofinnova Investments, Inc
0.05%
Abingworth Management Limited
0.03%
Baader Bank AG
0.03%
Schonfeld Strategic Advisors LLC
0.01%
Acadian Asset Management LLC
0.01%
Other
99.87%
Accionistas
Accionistas
Proporción
Sofinnova Investments, Inc
0.05%
Abingworth Management Limited
0.03%
Baader Bank AG
0.03%
Schonfeld Strategic Advisors LLC
0.01%
Acadian Asset Management LLC
0.01%
Other
99.87%
Tipos de accionistas
Accionistas
Proporción
Venture Capital
0.09%
Investment Advisor/Hedge Fund
0.04%
Hedge Fund
0.01%
Investment Advisor
0.01%
Other
99.85%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
51
579.39K
0.15%
+67.06K
2025Q1
52
492.36K
2.30%
-26.46K
2024Q4
52
469.91K
11.91%
+42.72K
2024Q3
52
279.81K
7.09%
-247.00K
2024Q2
51
362.89K
15.79%
-1.48K
2024Q1
59
340.51K
14.80%
-343.96K
2023Q4
65
549.25K
25.71%
-320.80K
2023Q3
68
668.24K
31.65%
-112.66K
2023Q2
71
571.34K
27.26%
-362.30K
2023Q1
81
667.89K
31.87%
-504.63K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Sofinnova Investments, Inc
199.52K
0.05%
+199.52K
--
Feb 14, 2025
Abingworth Management Limited
133.33K
0.03%
--
--
Apr 18, 2025
Baader Bank AG
10.03K
0%
+10.03K
--
Mar 31, 2025
Schonfeld Strategic Advisors LLC
44.77K
0.01%
-300.00
-0.67%
Mar 31, 2025
Acadian Asset Management LLC
38.32K
0.01%
-4.09K
-9.65%
Mar 31, 2025
XTX Markets LLC
20.16K
0.01%
+20.16K
--
Mar 31, 2025
Glass Jacobson Wealth Advisors
15.00K
0%
--
--
Dec 31, 2024
Griffith (Hugh S)
10.60K
0%
--
--
Dec 31, 2024
LUNIS Vermögensmanagement AG
8.90K
0%
-1.00
-0.01%
Sep 30, 2024
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Fecha
Tipo
Relación
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
